• 23 April 2018

    Tocagen licences cancer immunotherapy to ApolloBio

    US gene therapy company Tocagen has agreed to provide exclusive rights for biomedical firm ApolloBio to develop and commercialise its drug candidate, Toca 511 & Toca FC, in the greater...

  • 20 April 2018

    US FDA approves AstraZeneca’s Tagrisso for NSCLC

    The US Food and Drug Administration (FDA) has authorised AstraZeneca’s Tagrisso (osimertinib) drug as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)...

  • 19 April 2018

    FDA fast-tracks Roche’s Hemlibra for haemophilia A

    The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Roche’s Hemlibra, fast-tracking its development and review for the treatment of haemophilia A without factor VIII inhibitors.